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Background: Waist circumference, a metabolic syndrome (MetSy) criterion, is not routinely measured in clinical
practice making early identification of individuals with MetSy challenging. It has been argued that ratios of
commonly measured parameters such as lipids and lipoproteins may be an acceptable alternative for identifying
individuals with MetSy. The objective of our study was to explore clinical utility of lipid ratios to identify men and
women with MetSy; and to explore the association between lipid ratios and the number of MetSy components.
Methods: Men and women (N = 797) of Aboriginal, Chinese, European, and South Asian origin (35–60 years),
recruited across ranges of body mass index (BMI), with no diagnosed cardiovascular disease (CVD) or on
medications to treat CVD risk factors were assessed for anthropometrics, family history of CVD, MetSy components
(waist circumference, blood pressure, glucose, triglycerides (TG), high-density-lipoprotein-cholesterol (HDL-C)),
low-density-lipoprotein-cholesterol (LDL-C), nonHDL-C, and health-related behaviours.
Results: Mean levels of lipid ratios significantly increased with increasing number of MetSy components in men
and women (p < 0.05). After adjustment for age, ethnicity, smoking, alcohol consumption, physical activity, family
history of CVD and BMI, (and menopausal status in women), all lipid ratios were associated with the number of
MetSy components in men and women (Poisson regression, p < 0.001). Compared to the rest of the lipid ratios
(ROC curve analysis), TG/HDL-C was best able to discriminate between individuals with and without MetSy
(AUC = 0.869 (95% CI: 0.830, 0.908) men; AUC = 0.872 (95% CI: 0.832, 0.912) women). The discriminatory power of
TC/HDL-C and nonHDL-C/HDL-C to identify individuals with MetSY was the same (for both ratios, AUC = 0.793
(95% CI: 0.744, 0.842) men; 0.818 (95% CI: 0.772, 0.864) women). Additionally, LDL-C/HDL-C was a good marker for
women (AUC = 0.759 (95% CI: 0.706, 0.812)), but not for men (AUC = 0.689 (95% CI: 0.631, 0.748)). Based on a
multiethnic sample, we identified TG/HDL-C cut-off values of 1.62 in men and 1.18 in women that were best able
to discriminate between men and women with and without MetSY.
Conclusions: Our results indicate that TG/HDL-C is a superior marker to identify men and women with MetSy
compared to TC/HDL-C, LDL-C/HDL-C, and nonHDL-C/HDL-C.
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Metabolic syndrome is a cluster of metabolic abnormalities
associated with type 2 diabetes [1,2], cardiovascular mor-
bidity and mortality, and all-cause mortality [3,4]. It is
alarming that the prevalence of metabolic syndrome is high
and on the rise in both developed and developing countries
[5,6]. Early identification and treatment of individuals with
metabolic syndrome is imperative to prevent debilitating
consequences associated with its development. Regardless
of the approach for diagnosing metabolic syndrome, cen-
tral obesity, as measured by waist circumference, is one of
the main criteria for diagnosing metabolic syndrome
[7-10]. However, waist circumference is not routinely mea-
sured in primary care [11], which makes early identification
of individuals with metabolic syndrome challenging.
It has been argued that ratios of commonly measured
parameters such as lipids and lipoproteins may be an
acceptable alternative for identifying individuals with
metabolic syndrome [12-17]. Evidence shows that lipid
ratios perform better than individual lipids in predicting
cardiovascular risk [18-21]. Identifying a ratio to serve as
a quick and simple tool for identifying individuals at in-
creased cardiometabolic risk may decrease complexity of
and increase efficiency in identifying and monitoring
those at risk; especially as electronic medical records be-
come more commonplace or if useful biochemical ratios
were to be reported in routine laboratory test results.
However, research on clinical usefulness of lipid ratios to
identify individuals with metabolic syndrome is scarce
and mostly limited to specific population groups such as
Ghanian [17], Korean [14,16], Spanish [12], and Turkish
[13]. Furthermore, some of the available studies researched
limited number of ratios [13,17] or provided no cut-offs
for lipid ratios to help guide physicians in identifying
individuals at cardiometabolic risk [14,15]. Therefore,
the objective of this study was to explore the clinical
usefulness of lipid ratios to identify men and women
with metabolic syndrome. Lipid ratios researched
include: total cholesterol-to-high-density-lipoprotein-choles-
terol (TC/HDL-C), triglyceride-to-high-density-lipoprotein-
cholesterol (TG/HDL-C), low-density-lipoprotein-cholesterol-
to-high-density-lipoprotein-cholesterol (LDL-C/HDL-C), and
non-high-density-lipoprotein-cholesterol-to-high-density-
lipoprotein-cholesterol (nonHDL-C/HDL-C). In addition,
given that the number of metabolic syndrome components
has been shown to predict incident cardiovascular disease
(CVD) and type 2 diabetes [22], we additionally explored
the association of lipid ratios with the number of metabolic
syndrome components among men and women coming
from the ethnically diverse population.
Results
Participants were equally represented across sexes and
ethnicity. Compared to women, men had lower levels ofHDL-C and significantly higher levels of total cholesterol,
LDL-C, nonHDL-C, triglycerides, lipid ratios, glucose,
blood pressure, and waist circumference; also, alcohol
consumption was more prevalent among men than among
women (Table 1). Similarly, the average number of meta-
bolic syndrome components and prevalence of metabolic
syndrome were higher in men than in women.
Mean levels of lipid ratios were on average higher in
men than in women and significantly increased with in-
creasing number of metabolic syndrome components in
both men and women (Figure 1, Additional file 1: Table
S1). In both men and women, mean levels of lipid ratios
in individuals with zero metabolic syndrome components
were significantly lower from their counterparts with 1 or
more metabolic syndrome components (p < 0.05). In men
and women, except for LDL-C/HDL-C ratio, there was a
significant difference between mean levels of lipid ratios
across number of metabolic syndrome components
(p < 0.05). However, in both men and women, no signifi-
cant difference was found between mean levels of LDL-C/
HDL-C of participants with 3 and those with 4/5 meta-
bolic syndrome components (p > 0.05). Furthermore, the
results of partial correlation analyses (age and ethnicity
adjusted) reveal that in both men and women, compared
to the rest of the lipid ratios, TG/HDL-C showed stronger
correlations with waist circumference, blood pressure and
blood glucose (Additional file 2: Table S2). In addition, the
results of Poisson regression analyses indicate that, after
adjustment for age, ethnicity, smoking, alcohol consump-
tion, physical activity, family history of CVD and body
mass index (BMI) (and menopausal status in women), all
lipid ratios were significantly associated with the number
of metabolic syndrome components in both men and
women (Table 2).
Using ROC curve analyses, we plotted sensitivity over
1-specificity for each of the ratios in both men and
women (Figure 2). Compared to the rest of the lipid ra-
tios, TG/HDL-C was best able to discriminate between
apparently healthy men and women with and without
metabolic syndrome (AUC = 0.869 (95% CI: 0.830, 0.908)
for men; AUC= 0.872 (95% CI: 0.832, 0.912) for women).
The discriminatory power of TC/HDL-C and nonHDL-C/
HDL-C to identify individuals with metabolic syndrome
was the same (for both ratios, AUC= 0.793 (95% CI:
0.744, 0.842) for men; 0.818 (95% CI: 0.772, 0.864) for
women). In addition, based on Hosmer and Lemeshow’s
criteria [23] LDL-C/HDL-C was an “acceptable” marker to
discriminate between women with and without metabolic
syndrome (AUC = 0.759 (95% CI: 0.706, 0.812)), however
this was not the case for men (AUC = 0.689 (95% CI:
0.631, 0.748)). In both men and women, the analysis that
tested the statistical significance of the differences be-
tween areas under the curve revealed significant difference
between areas under the curves for all the pairs of lipid
Table 1 Distribution of risk factors in men and women
Men 380 Women 417 p value
Age (years) 46.8 ± 8.7 47.5 ± 8.9 0.241
Ethnicity 0.704
Aboriginal 81 (21.3%) 98 (23.5%)
Chinese 100 (26.3%) 118 (28.3%)
European 97 (25.5%) 99 (23.7%)
South Asian 102 (26.8%) 102 (24.5%)
Current smokers 44 (11.6%) 35 (8.4%) 0.133
Current consumers of alcohol 128 (33.7%) 98 (23.5%) 0.001
Physical activity (min/week) 226 (100, 447) 208 (95, 424) 0.269
Family history of cardiovascular disease 168 (44.2%) 187 (44.8%) 0.857
Waist circumference (cm) 92.6 ± 11.2 85.1 ± 12.2 <0.001
Body mass index (kg/m2) 27.6 ± 4.3 27.3 ± 5.3 0.498
TC (mmol/L) 5.25 ± 0.97 5.23 ± 1.03 0.776
HDL-C (mmol/L) 1.13 ± 0.29 1.43 ± 0.35 <0.001
LDL-C (mmol/L) 3.30 ± 0.85 3.17 ± 0.92 0.046
TC/HDL-C 4.91 ± 1.46 3.86 ± 1.23 <0.001
LDL/HDL-C 3.07 ± 1.01 2.35 ± 0.91 <0.001
nonHDL-C 4.12 ± 0.99 3.80 ± 1.05 <0.001
nonHDL-C/HDL-C 3.81 (2.93, 4.63) 2.68 (2.01, 3.45) <0.001
TG 1.48 (0.99, 2.22) 1.17 (0.83, 1.63) <0.001
TG/HDL-C 1.34 (0.82, 2.24) 0.86 (0.54, 1.22) <0.001
Systolic BP (mmHg) 117 (110, 124) 115 (106, 126) 0.025
Diastolic BP (mmHg) 79.2 ± 9.7 75.5 ± 9.2 <0.001
Glucose (mmol/L) 5.30 (5.00, 5.60) 5.10 (4.80, 5.40) <0.001
With MetSy 119 (31.3%) 104 (24.9%) 0.045
Number of MetSy components 1.84 ± 1.40 1.63 ± 1.22 0.026
Categorical variables presented as n (%), and sex differences were explored using Chi-square test. Continuous variables presented as mean ± SD if normally
distributed or median (25%, 75%) if skewed. Sex differences explored using t-test and Mann U Whitney test for normally distributed and skewed data, respectively.
TC – total cholesterol, HDL-C – high-density lipoprotein cholesterol, LDL-C – low-density lipoprotein cholesterol, TC/HDL-C – ratio of TC and HDL-C, TG – triglycerides,
TG/HDL-C – ratio of TG and HDL-C, nonHDL-C/HDL – ratio of nonHDL-C and HDL-C, LDL-C/HDL-C – ratio of LDL-C and HDL-C, MetSy – metabolic syndrome.
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and nonHDL-C/HDL-C for which AUCs were the same.
Lipid ratio cut-off values, with their respective sensitivities
and specificities, for identifying individuals with metabolic
syndrome are provided in Table 3.
Discussion
The purpose of this study was to explore the clinical utility
of lipid ratios to identify men and women with metabolic
syndrome. Additionally we explored the association bet-
ween lipid ratios and number of metabolic syndrome
components. Our results indicate that increases in lipid
ratios are significantly associated with increase in the
number of metabolic syndrome components in both men
and women after adjusting for age, ethnicity, smoking sta-
tus, alcohol consumption, physical activity, family history
of CVD, and BMI (and menopausal status in women).Compared to TC/HDL-C, LDL-C/HDL-C, and nonHDL-
C/HDL-C, TG/HDL-C was shown to be a better clinical
marker to discriminate between individuals with and with-
out metabolic syndrome. These results were consistent for
men and women.
The results of our study are in line with those based
on Spanish, Korean, and Japanese populations where in-
creases in lipid ratios were shown to be associated with
increase in the number of metabolic syndrome compo-
nents [12,14,15]. Our study extends the previous fin-
dings by reporting the positive association between lipid
ratios and the number of metabolic syndrome compo-
nents in a multiethnic population; this relationship per-
sisted after adjusting for ethnicity and other factors
known to be associated with metabolic syndrome.
The observed strong relationship between lipid ratios
and the number of metabolic syndrome components
AB
C
D
Figure 1 Mean levels of lipid ratios across number of metabolic
syndrome components in men and women (1A, 1B, 1C and 1D).
All means adjusted for age and ethnicity and presented as mean (95%
CI). *geometric means. Bonferroni-corrected pairwise comparisons
(0 vs. 1; 0 vs. 2; 0 vs. 3; 0 vs. ≥4; 1 vs. 2; 1 vs. 3; 1 vs. ≥4; 2 vs. 3; 2 vs. ≥4;
and 3 vs. ≥4 ): Men: Except for the pair 3 vs. ≥4 for LDL-C/HDL-C, all
other pairwise comparisons of means of TC/HDL-C, TG/HDL-C,
LDL-C/HDL-C and nonHDL-C/HDL-C across the number of metabolic
syndrome components were significant at p < 0.05. Women: Except for
the pair 3 vs. ≥4, all other pairwise comparisons of means of TC/HDL-C,
TG/HDL-C, LDL-C/HDL-C and nonHDL-C/HDL-C across the number of
metabolic syndrome components were significant at p < 0.05.
TG/HDL-C: triglyceride-to-high-density-lipoprotein-cholesterol, TC/HDL-C:
total cholesterol-to-high-density-lipoprotein-cholesterol, LDL-C/HDL-C:
low-density-lipoprotein-cholesterol-to-high-density-lipoprotein-
cholesterol, nonHDL-C/HDL-C: non-high-density-lipoprotein-cholesterol-
to-high-density-lipoprotein-cholesterol.
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identification of individuals with constellation of cardio-
metabolic abnormalities. However, the actual lipid ratio
cut-offs to guide clinicians in identifying individuals with
metabolic syndrome are rarely reported. The studies avail-
able looked at a limited number of lipid ratios and per-
tained to specific groups such as Spanish population [12]
or a population of Ghanian women [17]. We extend the
available findings by reporting lipid ratio cut-off values for
identifying men and women with metabolic syndrome.
According to our results, in both men and women,
TG/HDL-C was shown to be a better marker to identify
individuals with metabolic syndrome compared to TC/
HDL-C, LDL-C/HDL-C, and nonHDL-C/HDL-C. Based
on a multiethnic sample, we identified TG/HDL-C cut-off
values of 1.62 in men and 1.18 in women that were best
able to discriminate between men and women with and
without metabolic syndrome. These numbers were com-
parable but slightly lower than those reported by Cordero
et al. [12] who clinically assessed a large working popula-
tion of Spanish men and women and reported TG/HDL-Table 2 The association between lipid ratios and the
number of metabolic syndrome components
Men Women
Exp (B) (95% CI) Exp (B) (95% CI)
TC/HDL-C 1.262 (1.197, 1.330) 1.278 (1.204, 1.355)
ln_TG/HDL-C 1.875 (1.680, 2.092) 1.797 (1.603, 2.016)
LDL-C/HDL-C 1.236 (1.147, 1.332) 1.358 (1.243, 1.483)
ln_nonHDL-C/HDL-C 2.861 (2.258, 3.626) 2.633 (2.109, 3.286)
All Poisson regression models adjusted for age, ethnicity, smoking, alcohol
consumption, physical activity, family history of cardiovascular disease, and
BMI. Models for women additionally adjusted for menopause status. All
models significant at p < 0.001. TC/HDL-C – ratio of total cholesterol and
high-density lipoprotein cholesterol, TG/HDL-C – ratio of triglycerides and
high-density lipoprotein cholesterol, nonHDL-C/HDL – ratio of non-high-density
lipoprotein cholesterol and high-density lipoprotein cholesterol, LDL-C/HDL-C –
ratio of low-density lipoprotein cholesterol and high-density lipoprotein
cholesterol.
Aa,b, c,e, f
B
a,b, c,e, f
Figure 2 Receiver operating characteristic curves for evaluating the usefulness of lipid ratios to identify men (A) and women (B) with
metabolic syndrome. The diagonal line indicates a test with an area under the receiver operating characteristic curve of 0.5. The areas under
the curve for TC/HDL-C and nonHDL-C/HDL-C overlapped, as the discriminatory power of TC/HDL-C and nonHDL-C/HDL-C to identify individuals
with metabolic syndrome was the same. The difference between areas under the curve (p ≤ 0.01): aTG/HDL-C vs. TC/HDL-C. bTG/HDL-C vs.
nonHDL-C/HDL-C. cTG/HDL-C vs. LDL-C/HDL-C. dTC/HDL-C vs. nonHDL/HDL-C. eTC./HDL-C vs. LDL-C/HDL-C. fnonHDL-C/HDL-C vs. LDL-C/HDL-C.
TG/HDL-C: triglyceride-to-high-density-lipoprotein-cholesterol, TC/HDL-C: total cholesterol-to-high-density-lipoprotein-cholesterol, LDL-C/HDL-C:
low-density-lipoprotein-cholesterol-to-high-density-lipoprotein-cholesterol, nonHDL-C/HDL-C: non-high-density-lipoprotein-cholesterol-to-high-
density-lipoprotein-cholesterol.
Table 3 Results of receiver-operating curve analyses featuring the thresholds of lipid ratios with their respective
sensitivities and specificities for diagnosing metabolic syndrome in men and women
Men Women
Lipid ratio Criterion value (Sensitivity, specificity) Criterion value (Sensitivity, specificity)
TG/HDL-C 1.62 (84.0%, 80.1%) 1.18 (70.2%, 88.2%)
TC/HDL-C 5.05 (73.1%, 71.6%) 3.91 (81.7%, 68.7%)
LDL-C/HDL-C* 3.79 (40.2%, 88.5%) 2.53 (67.6%, 74.8%)
nonHDL-C/HDL-C 4.05 (73.1%, 71.6%) 2.91 (79.8%, 70.9%)
*According to the AUC, LDL-C/HDL-C showed to be a good marker of metabolic syndrome in women but not in men.
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and women with metabolic syndrome, respectively. The
observed differences in cut-offs reported in the above
mentioned study and the ones reported in this study are
most likely due to a difference in population groups
studied.
It has recently been reported that TG/HDL-C predicts
the development of CVD as effectively as the diagnosed
metabolic syndrome [24]. Similarly, TG/HDL-C was
found to predict coronary heart disease and CVD mor-
tality as well as or even better than does metabolic
syndrome in men [25]. However, the detection of an ele-
vated TG/HDL-C is not meant to replace metabolic syn-
drome diagnosis in clinical practice; and it should rather
be considered as a simple tool to quickly identify pa-
tients at increased cardiometabolic risk for whom fur-
ther risk evaluation and clinical intervention are needed
[25]. Indeed, it has recently been reported in the study
in young adults that, compared to metabolic syndrome
diagnostic, TG/HDL-C may be able to identify a greater
number of individuals at risk; however a use of a meta-
bolic syndrome diagnostics approach identifies individ-
uals with an accentuated cardiometabolic risk profile
[26]. While metabolic syndrome diagnosis may provide
more comprehensive approach to identifying present
cardiometabolic risk factors in individuals, this diagnos-
tics is challenged by the fact that waist circumference,
one of the integrative components of metabolic syn-
drome, is not commonly measured. Indeed, it has re-
cently been reported that WC is routinely measured by
only 6% of primary care physicians [11]. If translated, it
may mean that more than 90% of primary care physi-
cians would not be able to diagnose individuals with
metabolic syndrome given that one of its components is
not routinely measured. In contrast, both TG and HDL-C
are routinely measured in clinical practice, and TG/HDL-C
could be readily calculated (or provided by the laboratory)
to serve as a quick tool to identify men and women at
increased cardiometabolic risk. This approach to use
TG/HDL-C to identify individuals at risk for whom fur-
ther care is needed may reduce time and complexity for
initial diagnosis of people with constellation of cardiomet-
abolic abnormalities.
Other research groups have also proposed TG/HDL-C
as a potential, simple tool to identify patients at in-
creased risk for CVD. The evidence shows a strong as-
sociation between TG/HDL-C and insulin resistance as
measured by glucose clamp [27,28], modified insulin
suppression test [29], and homoeostasis model assess-
ment index [29,30]. This association was also found to
be independent of waist circumference [31]. Further,
others found TG/HDL-C to be an independent predictor
of future type 2 diabetes mellitus [25,32] and its related
microvascular complications [33]; coronary heart disease[34,35]; major cardiovascular events including overall
death, myocardial infarction, and unstable angina that
required revascularization [36] and those including an-
gina pectoris, myocardial infarction, myocardial revas-
cularization, and fatal or nonfatal stroke [37]; and first
coronary event irrespective of BMI [38]. The strong rela-
tionship between TG/HDL-C and CVD may be founded
in the atherogenic properties of TG/HDL-C. It has been
reported that increase in TG/HDL-C is significantly as-
sociated with decrease in LDL particle size and increase
in fractional esterification rates of cholesterol in plasma
depleted of apoB-lipoproteins; hence the proposed name
for TG/HDL-C being atherogenic index of plasma [39].
In light of available evidence, including the results of our
study, it seems reasonable to conclude that TG/HDL-C
may serve as a useful marker to identify individuals at
increased risk of CVD.
Several limitations to our study should be considered.
This study is a cross-sectional design, thus longitudinal
studies are needed to explore whether the association
between TG/HDL-C and metabolic syndrome persists or
changes over time in men and women. Further, the
M-CHAT participants were recruited across a range of
BMI, so this study may not be representative of the
general population. However, recruiting people across
ranges of BMI allows for the opportunity to explore the
associations between lipid ratios and metabolic syndrome
in the population with a range of body sizes. Also, the re-
sults of our analyses indicate a significant association bet-
ween lipid ratios and number of metabolic syndrome
components independent of BMI. Moreover, our analyses
were adjusted for age, ethnicity, smoking, status, alcohol
consumption, physical activity, family history of CVD and
BMI (and menopausal status in women) but not for diet
known to influence plasma TG levels. Of importance, TG/
HDL-C cut-points for identifying individuals at risk may
vary across ethnicity and race [40,41]. Also, TG/HDL-C
was shown not to be a reliable risk marker in individuals
of South Asian [41] and African American origin [42,43].
While statistical power did not allow us to additionally
stratify our analyses by ethnicity, given the established
ethnic differences in the way body fat is accumulated
[44,45] and ethnic differences in cardiometabolic risk
[46,47], we believe that further research featuring ethnic-
specific analyses is warranted.
Conclusions
In conclusion, our study shows strong positive associ-
ation between lipid ratios and metabolic syndrome in
apparently healthy men and women (without CVD and
not on CVD-related medications) drawn from an eth-
nically diverse population. TG/HDL-C appeared to be a
superior marker compared to TC/HDL-C, LDL-C/HDL-C,
and nonHDL-C/HDL-C, and it is useful for identifying
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TG/HDL-C readings of 1.62 or greater in men and 1.18 or
greater in women can help primary care physicians easily
identify individuals at increased risk for CVD. Early identi-
fication of individuals at risk would allow for an early im-
plementation of lifestyle and medication strategies, while
TG/HDL-C could be further used to evaluate the success
of such strategies.
Methods
Apparently healthy men and women were recruited as
part of the Multi-Cultural Community Health Assessment
Trial (M-CHAT) designed to compare body fat distribu-
tion of Aboriginal, Chinese, and South Asian populations
to that of a European population and explore how fat
distribution relates to CVD risk factors [48]. Details on re-
cruitment of study participants have already been pub-
lished [48]. In brief, eligible participants were apparently
healthy individuals between ages of 30 and 65 of Aborigi-
nal, Chinese, European and South Asian origin residing in
the Vancouver mainland. To ensure a range of body fat
mass across groups, participants were recruited from the
following BMI (kg/m2) ranges: 18.5-24.9 (low range), 25.0-
29.9 (middle range), and 30 and over (upper range). Given
that it was challenging to identify Aboriginal men with a
BMI of less than 25, Aboriginal men of any BMI were re-
cruited. Similarly, due to a difficulty in identifying Chinese
individuals with a BMI of 30 kg/m2 and higher, the target
for the upper BMI range was changed to a BMI of 28 and
higher. Individuals with a fluctuation in weight that was
greater than 2.5 kg three months prior to the assessment
date, and those with diagnosed CVD or on medications to
treat CVD risk factors, were not eligible for the study.
Ethnicity was self-reported. All study participants pro-
vided informed consent for the study, and the study was
approved by the Simon Fraser University Research Ethics
Board.
All participants were assessed for socio-demographics
and risk factors. Following the standard protocols for
blood sample collection, shipment, and processing, fast-
ing blood samples were collected from each participant
at the research site and assessed for lipids and glucose at
St. Paul’s Hospital in Vancouver, Canada. Glucose, TC,
TG, and HDL-C were determined using standard proto-
cols by ADVIA 1650 analyzer (Bayer Health Care, LLC.,
New Jersey, USA). Friedwald formula was used to calcu-
late LDL-C [49]. Height and weight were measured, and
BMI was calculated as weight in kilograms divided by
height in metres squared. Waist circumference repre-
sented an average of two measurements taken upon ex-
piration at the mid point between the low rib margin
and iliac crest. Blood pressure was recorded as mean of
5 measurements taken after 10 minutes seated rest in
the left arm using BpTRU model BPM-200 oscillometricoffice blood pressure monitor (VSM MedTech Ltd.,
Coquitlam, British Columbia). Smoking status (current
smokers/non-smokers), alcohol consumption (currently
consume alcohol/do not consume alcohol) and family
history of CVD (yes/no) were determined by self-report.
Women self-reported their menopausal status by choos-
ing from the following options (women were provided a
definition for each of the options): pre-menopausal
(regular menstrual cycles), peri-menopausal (menopausal
transition with symptoms such as menstrual irregu-
larity), post-menopausal (end of menstrual cycles, at
least 12 months since the last menstrual period), or hys-
terectomy (surgical removal of the uterus). Menopausal
status variable used as a confounder in regression
analyses consisted of two categories, pre-menopausal
(pre-menopausal and peri-menopausal) and menopausal
(post-menopausal and hysterectomy). Physical activity
was measured using the Modifiable Physical Activity
questionnaire previously used in multi-ethnic popula-
tions and determined by self-report [50,51]. A person
would qualify as having metabolic syndrome if he/she
had three out of 5 risk factors present (hypertension,
hypertriglyceridaemia, lowered HDL-C, hyperglycaemia,
and central obesity) using the most recent harmonized
definition of the metabolic syndrome where ethnic spe-
cific thresholds for waist circumference were used [10].
Statistical analyses
Only participants with complete data for all metabolic syn-
drome components were included to the study (N = 797).
Considering significant sex differences in body fat distribu-
tion and cardiometablic risk [52-54], all statistical analyses
were performed separately for men and women. Cate-
gorical variables were presented as counts and percent-
ages, and differences between men and women were
explored using Chi-square test. Continuous variables were
presented as means ± standard deviation (SD) if normally
distributed, or medians with 25th and 75th percentiles if
not normally distributed. Differences between men and
women in the distribution of continuous variables were
explored using t-test and Mann U Whitney test for nor-
mally distributed and skewed data, respectively.
Age and ethnicity adjusted levels of lipid ratios across
the number of metabolic syndrome components were
determined using general linear modelling (Bonferroni-
corrected post hoc comparisons). In our apparently
healthy multiethnic study population, there was a limited
number of participants with 4 (n = 66) and 5 (n = 18)
metabolic syndrome components; therefore, we com-
bined these two categories. Poisson regression analysis
was used to explore the association between lipid ratios
and the number of metabolic syndrome components. All
models were adjusted for age, ethnicity, smoking, alcohol
consumption, physical activity, family history of CVD
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for menopausal status.
The clinical utility of lipid ratios to identify individuals
with metabolic syndrome was explored using receiver-
operating characteristic curve (ROC) analysis. Plots of
sensitivity (true positives) versus 1 minus specificity (false
positives) were constructed in both men and women for
each lipid ratio. Area under the curve (AUC) was calcu-
lated to explore which lipid ratio showed highest accuracy
in predicting metabolic syndrome. AUC is a measure of
discrimination, and AUC of 0.5, 0.6 ≤AUC< 7, 7 ≤AUC<
0.8, 0.8 ≤AUC< 0.9, and ≥ 0.9 corresponds to no discri-
mination, poor, acceptable, excellent, and outstanding
discrimination, respectively [23]. Optimal cut-off point of
each lipid ratio to identify individuals with metabolic syn-
drome corresponded to a maximum value of Youden
index that was calculated as sensitivity + specificity – 1
[55,56]. Additionally, the statistical significance of the dif-
ference between areas under the curves was tested using
the methods of De Long et al. [57]. Analyses were per-
formed using Statistical Package for Social Sciences (SPSS)
version 19 except for the comparisons of ROC curves that
were performed using MedCalc statistical software.
P values of less than 0.05 were considered statistically
significant.
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